Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

NCT06895733 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor, Adult
Next-generation Sequencing
Precision Medicine

Interventions

DRUG: Pazopanib Oral Tablet
DRUG: Palbociclib

Sponsor

Tianjin Medical University Second Hospital